Panagora Asset Management Inc Akebia Therapeutics, Inc. Transaction History

Panagora Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	BUY	$0.72 - $2.93 $167 - $682	233 Added 0.09%	250,894 $180,000
Q4 2021 Feb 10, 2022	BUY	$2.26 - $3.34 $1,911 - $2,825	846 Added 0.34%	250,661 $566,000
Q3 2021 Nov 10, 2021	BUY	$2.35 - $3.88 $421,188 - $695,408	179,229 Added 253.92%	249,815 $719,000
Q2 2021 Aug 11, 2021	BUY	$2.83 - $4.2 $199,758 - $296,461	70,586 New	70,586 $268,000
Q4 2020 Feb 10, 2021	SELL	$2.22 - $3.78 $67,681 - $115,240	-30,487 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$2.39 - $13.08 $72,863 - $398,769	30,487 New	30,487 $77,000
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $1.19 Million - $1.48 Million	-130,574 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$9.53 - $15.68 $152,194 - $250,409	-15,970 Reduced 10.9%	130,574 $1.24 Million
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $1.66 Million - $2.28 Million	116,418 Added 386.44%	146,544 $2.18 Million
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $393,445 - $592,578	30,126	30,126 $593,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $417M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.